# Zilxi - (1.50% ; Topical Aerosol Foam)

| | | | |
|---|---|---|---|
| **Generic Name** | Minocycline Hydrochloride | **Innovator** | Journey medical corp |
| **Dosage** | 1.50% ; Topical Aerosol Foam | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | Less Than 5 |
| **Other ANDA developers** | None | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | Zilxi is a tetracycline-class drug indicated for the treatment of inflammatory lesions of rosacea in adults. | | |
| **Complexities** | Yes | | |

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.